GBL acquires a majority stake in Sanoptis, a European leader in ophthalmology clinics, to accelerate the company’s growth in partnership with its management and doctors

GBL

Groupe Bruxelles Lambert (“GBL”) has signed definitive agreements to acquire a majority stake in Sanoptis,
a leading network of ophthalmology clinics across Germany and Switzerland, from Telemos Capital (“Telemos”). GBL
is committing up to EUR 750 million in equity for this transaction. As part of the transaction, the incumbent
management will increase its stake in the company by way of a substantial reinvestment. GBL and management plan
to continue together the impressive growth story of Sanoptis, both in existing markets as well as in new, attractive
European geographies.

Founded in 2018, Sanoptis has rapidly grown to become the second largest European ophthalmology services provider
with over 250 facilities, serving both publicly and privately insured patients. For GBL and management, the ambition
will be to continue Sanoptis’ growth organically and through acquisitions. The company will remain focused on
adhering to the highest quality standards while delivering essential medical services of the highest grade to the
German and Swiss population in partnership with local regulators and payors. Further growth will increase the depth
and breadth of these high-quality services.
Sanoptis has a unique business model; it targets active partnerships with leading surgeons who remain shareholders
in their clinics after joining the Sanoptis group. Within its network, Sanoptis drives growth by: (i) sharing medical and
other best practices while preserving the doctors’ autonomy and (ii) implementing cutting-edge medical innovations
while investing in top-notch equipment. GBL strongly believes in this partnership model and envisions to further
grow Sanoptis along the same strategy.

This transaction marks GBL’s second consecutive private investment in the healthcare sector in 2022. Healthcare is one
of GBL’s four focus investment sectors, along with consumer experience, technology and sustainability. The Sanoptis
transaction also corresponds to GBL’s ambition to increase the representation of controlled private and alternative
assets within its portfolio. The group’s long-term objective is that private and alternative investments account for
approximately 40% of its portfolio (versus 25% as of end 2021).
Ian Gallienne, CEO of GBL, commented: “As a private asset in the highly-attractive healthcare sector, Sanoptis is an excellent
fit with our investment strategy. Together with management, we look forward to further solidifying Sanoptis’ leadership positions
in its core markets as well as expanding into other European countries.”
Michal Chalaczkiewicz, GBL Investment Partner, added: “Sanoptis is at the forefront of the ophthalmology field, which is
supported by long-term, resilient growth, underpinned by secular trends. We believe Sanoptis’ unique partnership model with
doctors is its most important asset, which will support the continuation of its impressive growth trajectory.”
Jens Riedl, GBL Investment Partner responsible for the DACH region, stated: “After our acquisition of Canyon,
the fast-growing direct-to-consumer manufacturer and seller of premium bicycles, Sanoptis is our second private investment in
DACH, where we have the opportunity to team up with an exceptional team of entrepreneurs.”
For Volker Wendel, Founder and CEO of Sanoptis: “We are excited to continue our success story with a strong and
sustainable partner who fully supports our doctor-oriented culture and entrepreneurial strategy. Continuing business in the same
way as we did in the last four years, we see a lot of potential for future growth in DACH and other European countries. That’s
why management remains fully committed and will substantially increase its stake in the company.”
GBL has been advised by Goldman Sachs, Bain & Company, EY and Kirkland & Ellis.

Delivering meaningful growth
Privileged and regulated information – April 20, 2022 // Page 2 / 2 // For more information: www.gbl.be
The transaction is expected to be completed in the second quarter of 2022.
For more information, please contact:
Xavier Likin Alison Donohoe
Chief Financial Officer Head of Investor Relations
Tel: +32 2 289 17 72 Tel: +32 2 289 17 64
xlikin@gbl.be adonohoe@gbl.be

About Sanoptis
Sanoptis is a leading German and Swiss ophthalmology services provider with approximately EUR 300 million of
revenue in 2021. Founded in 2018 by CEO Volker Wendel and CDO Carsten Horn, Sanoptis has rapidly grown to
become a leading European ophthalmology services provider, with over 250 facilities across Germany and
Switzerland, serving both publicly and privately insured patients. The company offers both conservative
ophthalmology consultations and surgical treatments including cataract surgeries, intravitreal operative medicine
injections (IVOM), laser eye surgeries and retina surgeries. Sanoptis performs over 1.3 million consultations and
170,000 surgical procedures annually, while adhering to the highest standards of healthcare through its leading
doctor base and thorough quality management.

About Telemos Capital
Telemos comprises a team of highly experienced investment professionals that combine the best of private equity
and permanent capital. Founded in 2017, Telemos identifies and supports exceptional management teams in
consumer goods, healthcare services, and business services to help them realise their long-term objectives. As a
flexible and nimble investor, Telemos’ distinct structure and expertise make it a leading, new generation European
private equity firm, looking to identify and unlock attractive opportunities for growth and value creation.

About Groupe Bruxelles Lambert
Groupe Bruxelles Lambert (“GBL”) is an established investment holding company, with over sixty years of stock
exchange listing, a net asset value of EUR 22.5 billion and a market capitalization of EUR 15.3 billion at the end of
December 2021. GBL is a leading investor in Europe, focused on long-term value creation and relying on a stable and
supportive family shareholder base. GBL is both a responsible company and investor and perceives ESG factors as
being inextricably linked to value creation.
GBL strives to maintain a diversified high-quality portfolio of listed and private assets as well as alternative
investments (through Sienna Investment Managers, the group’s alternative investment platform), composed of
international companies that are leaders in their sectors, to which it can contribute to value creation by being an
active, supportive and professional investor.
GBL is focused on delivering meaningful growth by providing attractive returns to its shareholders through a
combination of growth in its net asset value, a sustainable dividend and share buybacks.
GBL is listed on the Euronext Brussels stock exchange (Ticker: GBLB BB; ISIN code: BE0003797140) and is included
in the BEL20 index

Categories: News

Tags:

CVC Fund VI agrees exit of Theramex

CVC Capital Partners

28 Mar 2022

Global investment firms PAI Partners and Carlyle (NASDAQ: CG) today announce that they have agreed to acquire Theramex, the leading global specialty pharmaceuticals company focused on women’s health, from CVC Capital Partners VI (“CVC”).

Theramex was created following the carve-out of a portfolio of women’s health pharma products in 2018, and has subsequently developed into one of the largest specialty pharma platforms dedicated to women and their health. The company provides patient-focused solutions across contraception, fertility, menopause, and osteoporosis with the aim of providing patients with products that can support them through their life journey. Under CVC Funds’ ownership, Theramex has focussed on building loyal relationships with physicians through its dedicated sales force, investing in digital capabilities and executing a successful M&A agenda to bring new products to market in the future, resulting in double digit revenue and EBITDA growth since 2018.  The company now serves more than six million women in 57 countries across EMEA, APAC and South America, and employs approximately 480 people (~60% of whom are women).

With the support of Carlyle and PAI Partners, Theramex will seek to expand its diverse suite of products across existing and adjacent therapeutic areas and accelerate international expansion. The investment in Theramex builds on Carlyle’s long-term global focus on Healthcare, a sector in which the firm has invested $15 billion to date. Carlyle has significant expertise in scaling global Pharma businesses, such as iNova, Curia and PPD, and specifically in women’s health, through its investment in Millicent Pharma. Similarly, PAI will utilise its deep sector experience in healthcare to support Theramex’s growth trajectory. Healthcare is one of PAI’s four core sectors of focus, in which the firm has made ten investments, including in pharmaceutical companies, Ethypharm and Ipsen.

Robert Stewart, CEO of Theramex said: “I am delighted to have the support of both Carlyle and PAI Partners investing in the business, which will allow us to further accelerate our growth. I also want to thank CVC for being such a fantastic partner over the last years. Together, we have built one of the world’s largest pharmaceutical companies dedicated solely to women’s health, improving lives and ensuring these important products are made available to all who need them.”

Sebastien Veil and Andreas Kumeth, both Partners at PAI, said: “We were attracted to Theramex given its strong heritage in women’s health and outstanding reputation for delivering effective and safe solutions that support and care for women around the world. We look forward to leveraging PAI’s extensive healthcare network and capital to support organic and inorganic growth initiatives for Theramex and partnering with the management team to support the continued expansion of the platform.”

Lubna Qunash and Philipp Meyer, both Managing Directors of the Carlyle Europe Partners advisory team, said: “We believe that Theramex’s long-standing and established position as a women’s health champion with a broad and complementary product portfolio are distinctive attributes which position the business well for continued success. This acquisition demonstrates our strategic commitment to the Healthcare sector in Europe, and together with PAI, we look forward to partnering with the Theramex management team and utilising our significant resources and global network to support their international growth ambitions.”

Cathrin Petty, a Managing Partner and Global Head of Healthcare at CVC, said: “Theramex has been at the forefront of raising awareness and delivering better therapies for women across the globe, particularly in relation to menopause, endometriosis and osteoporosis. As a team, we are very proud to have supported the fantastic Theramex leadership, from the head office through supply chain experts, through to the country leadership and our dedicated sales force – all of whom have a dedication to making a difference to women’s lives. We wish the team every success in the next chapter of growth.”

Carlyle and PAI Partners were jointly advised by Morgan Stanley, Jefferies and Greenhill & Co (M&A), and Linklaters and Allen & Overy (Legal), and PwC (Financial). CVC was advised by Rothschild & Co, HSBC (M&A) and Latham & Watkins (Legal), and EY (Financial), and IQVIA (Commercial).

The financial terms of the transaction are not being disclosed.

Categories: News

Tags:

Audax Private Equity Announces Agreement to Sell Lifemark Health Group to Loblaw Companies Limited

Audax Group

Audax Private Equity (“Audax”) today announced that it has entered into a definitive agreement to sell Lifemark Health Group (“Lifemark” or the “Company”), a leading provider of physiotherapy, rehabilitation, and medical assessments in Canada, to Loblaw Companies Limited (TSX: L) (“Loblaw”).

Headquartered in Toronto, ON, Lifemark is a leading provider of outpatient physiotherapy, massage therapy, occupational therapy, chiropractic, mental health, and other ancillary rehabilitation services. With over 20 years of service, Lifemark is one of the largest and most trusted providers in Canada. As a national healthcare company, Lifemark employs over 5,000 highly trained clinicians, medical experts, and team members in over 300 locations across Canada.

Since partnering with Audax in December 2015, Lifemark has completed over 50 acquisitions, broadened its service offering, and significantly expanded its national footprint. In partnership with Audax, Lifemark also invested heavily in the organic growth of its platform, systems, and key talent to support and sustain continued success.

“Peter and the Lifemark team created a phenomenal business built on the foundation of excellent clinical service,” said Keith Palumbo, Managing Director at Audax Private Equity. “The outpatient physical therapy industry remains highly fragmented and vast, and we’re very proud of the growth we were able to achieve at Lifemark through facility utilization gains, geographic expansion, new services, and acquisitions. We wish them all the best as they continue their journey with Loblaw.”

“At Lifemark, we continually look for the most impactful ways to support Canadians on their healthcare journey, and we are grateful to our partners at Audax for helping us to invest in and develop opportunities that advance physiotherapy and rehabilitation services in Canada,” said Peter Stymiest, Chief Executive Officer of Lifemark Health Group. “We look forward to what the future holds for our patients, clients, and team in partnership with Loblaw.”

The sale of Lifemark is subject to regulatory approvals and other customary closing conditions. The transaction is expected to close in the second quarter of 2022.

Harris Williams is serving as financial advisor and Blake, Cassels & Graydon LLP and Kirkland & Ellis LLP are acting as legal advisors to Audax Private Equity.

Categories: News

Tags:

AEVIS VICTORIA SA sells its participation in Medgate to Otto Group

Aevis Victoria

AEVIS VICTORIA SA / Key word(s): Disposal

10-March-2022 / 17:45 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


Ad hoc announcement pursuant to Art. 53 LR

Fribourg, 10 March 2022

AEVIS VICTORIA SA sells its participation in Medgate to Otto Group

In 2016, the investment company AEVIS VICTORIA SA (AEVIS) acquired a 40% minority stake in Medgate Group, which has now become the leading telemedicine provider in Switzerland with over 20 years of experience. AEVIS has accompanied and financially supported the development of Medgate for 6 years, allowing the creation of a key player in the telemedicine sector in Europe. In the context of a financing round initiated by Medgate in 2021 to finance various acquisitions, amongst others in Germany, AEVIS has sold its participation to the German Otto Group, which will take over this role and accompany Medgate for its further expansion. The proceeds of the sale will significantly strengthen AEVIS’s financial capacity and will be redeployed in its investment activities. The parties have agreed not to disclose the details of the transaction.

For further information:
AEVIS VICTORIA SA Media and Investor Relations: c/o Dynamics Group, Zurich
Philippe R. Blangey, prb@dynamicsgroup.ch, +41 (0) 43 268 32 35 or +41 (0) 79 785 46 32
Séverine Van der Schueren, svanderschueren@aevis.com, +41 (0) 79 635 04 10

AEVIS VICTORIA SA – Investing for a better life
AEVIS VICTORIA SA invests in healthcare, hospitality & lifestyle and infrastructure. AEVIS′s main shareholdings are Swiss Medical Network SA (90%, directly and indirectly), the only Swiss private network of hospitals present in the country’s three main language regions, Victoria-Jungfrau AG, a luxury hotel group managing ten luxury hotels in Switzerland and abroad, Infracore SA (30%, directly and indirectly), a real estate company dedicated to healthcare-related infrastructure, Swiss Hotel Properties SA, a hospitality real estate division, and NESCENS SA, a brand dedicated to better aging. AEVIS is listed on the Swiss Reporting Standard of the SIX Swiss Exchange (AEVS.SW). www.aevis.com.

 

Additional features:

File: AEVIS VICTORIA SA sells its participation in Medgate to Otto Group


End of ad hoc announcement

Categories: News

Tags:

Better quality of care in outpatient rehabilitation: Gimv portfolio company rehaneo acquires Reha Vita

Topic: Investment

The Munich-based rehaneo Group, one of Germany’s leading providers of outpatient rehabilitation, is integrating Reha Vita in Cottbus, Brandenburg’s largest outpatient rehabilitation centre. In doing so, rehaneo is continuing its consistent growth trajectory and doing everything that it can to ensure that more people can access professional rehabilitation measures close to where they live. Since its foundation mid-2020, the company has been supported by the investment firm Gimv, which recognizes the increasing importance of top-quality outpatient service provision for rehabilitation and has helped to shape the strategy from the very beginning.

rehaneo (www.rehaneo.de) is a rapidly growing provider of outpatient rehabilitation, aftercare, prevention and occupational health management in Germany. Around 18 months ago, Gimv and rehaneo’s managing partner Bruno Crone launched the company as a buy-and-build project with the goal of developing a leading network offering patients access to top-quality, local outpatient care. In doing so, rehaneo is addressing a fragmented growth market as more and more patients want to live at home during their rehabilitation. This improves patients’ quality of life, while the costs of outpatient rehabilitation are also around 40% lower than for inpatient care – for the same quality or even better quality – thereby reducing the burden on the payers.

“rehaneo offers rehabilitation centres a strong partner and an orderly succession opportunity. In addition to our professional competence, we are also placing an emphasis on appreciation and clear values. It is for example important to us to maintain and strengthen the unique character of our rehabilitation centres”, explains Crone. Based on this philosophy, rehaneo was able to win the rehabilitation centre Hunsrück and insa health management still in the founding year 2020. In 2021, the group was able to add rehabilitation centres in Koblenz, Bonn and Göttingen. The recently completed sixth acquisition Reha Vita in Cottbus, has developed from a small physiotherapy practice into a rehabilitation centre with more than 140 employees. In total, the rehaneo group today has more than 600 employees that care for a total of around 30,000 patients and customers a year and support them on their path to a rapid recovery.

Group strategy bears fruit

“From the very beginning, we were enthusiastic about the vision of establishing a leading quality provider in outpatient rehabilitation and we are proud of what has been achieved in such a short period of time”, notes Philipp v. Hammerstein, Partner and the manager responsible for Gimv’s health & care activities in Europe’s German-speaking regions. “We are delighted to be able to actively support rehaneo’s management team with our expertise as an investor specializing in healthcare”, adds Lars Timmer, Principal at Gimv. rehaneo’s strong positioning will be further expanded through additional acquisitions as well as the targeted development of existing rehabilitation centres and the establishment of new ones. The trusting collaboration between Gimv and the management team is a decisive component here. “From day one, we were convinced that Gimv is perfectly suited to us. It has proven to be an agile, hands-on partner with an unparalleled knowledge of the market”, confirms Crone.

Already today, rehaneo sets itself apart through excellent scores in terms of quality and patient satisfaction, advanced digitization with an innovative patient app, a clear commitment to ESG criteria and, not least, a high level of employee satisfaction. “We specifically search for successful, well-established outpatient rehabilitation centres and remedy providers that share our values and recognise the advantages of working together as a larger group”, explains Bruno Crone. “Whether in negotiations with suppliers, through group-wide economies of scale and synergy effects or in terms of further training and education, a group can achieve much more than a standalone centre.”

Categories: News

Tags:

EQT closes acquisition of LSP and introduces EQT Life Sciences

Following the signing of a definitive agreement as announced on 10 November 2021 to acquire LSP (the “Transaction”), EQT AB (“EQT”) is pleased to announce that the Transaction was completed on 28 February 2022. All necessary closing conditions, including regulatory, anti-trust and fund investor clearances, have been achieved.

At completion of the Transaction, René Kuijten, previously Managing Partner at LSP, is appointed Partner and Head of EQT Life Sciences, a newly formed business line within EQT’s Private Capital business segment.

The total consideration is EUR 475 million (which includes an earn-out payment of EUR 25 million, as the short-term fundraising targets for such earn-out have been met), and as partial payment of this total consideration, EQT has issued 7,548,384 shares to LSP’s selling shareholders, corresponding to a dilution of approximately 0.8 percent. EQT will have 993,828,524 ordinary shares issued and outstanding following the completion of the Transaction.

Per Franzén, Partner and Head of EQT Private Capital, said, “We are pleased to have closed the acquisition of LSP. Joining forces with LSP will further strengthen EQT’s industry leading position within healthcare and improve our ability to invest in and future-proof the most attractive companies in the healthcare sector. I am truly excited to welcome René Kuijten and his entire team to the EQT family.”

René Kuijten, Partner and Head of EQT Life Sciences, said, “On behalf of the entire LSP team, I want to express my excitement of joining EQT and forming EQT Life Sciences. Having access to the EQT platform’s fundraising capabilities, healthcare sector teams, and in-house expertise within digitalization and sustainability brings unique collaboration opportunities and is a win-win for all our stakeholders.”

On 11 February 2022, LSP announced that it had held the final close of its new flagship fund LSP 7 at EUR 1 billion, making it the largest life sciences venture capital fund ever raised in Europe to date. The fund aims to invest in companies developing new drug therapies and medical technologies, to help ensure that their scientific innovations benefit patients.

Contact
EQT Press Office, press@eqtpartners.com, +46 8 506 55 334

About EQT Life Sciences
EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs the smartest inventors who have ideas that could truly make a difference for patients. The team combines deep sector knowledge, analytical skills, and investment experience to provide the added value that inventors seek. EQT Life Sciences’ broad life sciences and healthcare network is highly complementary to EQT’s global healthcare sector franchise and makes EQT an even better and more innovative healthcare investor.

About EQT
EQT is a purpose-driven global investment organization focused on active ownership strategies. With a Nordic heritage and a global mindset, EQT has a track record of almost three decades of delivering consistent and attractive returns across multiple geographies, sectors and strategies. EQT has investment strategies covering all phases of a business’ development, from start-up to maturity. EQT today has EUR 73.4 billion in assets under management across 28 active funds within two business segments – Private Capital and Real Assets.

With its roots in the Wallenberg family’s entrepreneurial mindset and philosophy of long-term ownership, EQT is guided by a set of strong values and a distinct corporate culture. EQT manages and advises funds and vehicles that invest across the world with the mission to future-proof companies, generate attractive returns and make a positive impact with everything EQT does.

The EQT AB Group comprises EQT AB (publ) and its direct and indirect subsidiaries, which include general partners and fund managers of EQT funds as well as entities advising EQT funds. EQT has offices in 24 countries across Europe, Asia-Pacific and the Americas and approximately 1,200 employees.

More info: www.eqtgroup.com

Follow EQT on LinkedIn, Twitter, YouTube and Instagram

Categories: News

Tags:

Biolam, the French group of medical laboratories, accelerates

GIMV

Daniel Attias and Gimv continue their organic and external growth strategy in Hauts-de-France and Normandy, enabling Biolam – a group of medical laboratories – to exceed EUR 60 million in turnover (pro forma of the latest acquisitions).

Starting from scratch in 2019, Daniel Attias was supported by Gimv in his first MBI takeover of the Biolam group of laboratories in Amiens. Didier Thibaud joined in 2020 to strengthen the Biolam presence in Normandy. Today, this duo is pursuing an accelerated growth strategy. After four acquisitions and four laboratory creations in 2020, Biolam (www.groupebiolam.fr ) realised three new acquisitions over 2021. The group has consolidated its position in Normandy with the acquisition of Boyer Laboratories, contributing approximately EUR 8 million in additional turnover. In the Hauts-de-France region, Biolam acquired the Mine laboratories in the Valencienne region, where it began its growth by opening two laboratories (Marly and La Madeleine), as well as the acquisition of the Tabardel and Viart laboratory in Béthune.

In 2022, Biolam intends to continue its organic growth with the opening of 6 new laboratories, several acquisitions under negotiation and significant investments in the renewal of its industrial equipment, in Normandy as well as in the Hauts-de-France.

The success of this buy-and-build platform demonstrates once again that the Gimv Health & Care team, together with ambitious management teams, is expert in consolidation projects in Europe.

Gautier Lefebvre, Partner at Gimv, and Kevin Klein, Principal at Gimv, state: “We are impressed by the trajectory of Biolam, which, under the leadership of Daniel Attias and Didier Thibaud, continues to grow extremely fast while investing heavily in its teams and tools in order to build a high quality healthcare offering. This entrepreneurial adventure is a perfect illustration of our ability to support managers in rapid external growth strategies. Over the past two years, Gimv’s Health & Care team has completed 32 acquisitions via 6 build-up platforms.”

Daniel Attias, Chairman of the Biolam Group, says: “We have already exceeded the targets we initially set ourselves with the Gimv team, which is a sign of a very effective collaboration. We start 2022 with great ambitions in a sanitary context where our willingness to invest, our agility and the total engagement of our teams are more necessary than ever.”

Categories: News

Tags:

Reliance Health raises $40M in Series B led by General Atlantic

General Atlantic

Growth investment will fuel continued growth in Nigeria, expansion into additional emerging markets, and allow for the scaling of product lines such as diaspora plans.

Reliance Health, an emerging markets-focused digital healthcare provider, today announced the completion of a $40M Series B funding round led by General Atlantic, a leading global growth equity investor, with participation from Partech, Picus Capital, Tencent Exploration, AAIC (Asia Africa Investment and Consulting), P1 Ventures, Laerdal Million Lives Fund, M3, Inc., and Arvantis Social Foundation. With this funding, Reliance Health has successfully closed the largest Series B round in the African HealthTech industry to date. The newly-established partnership also marks General Atlantic’s first technology investment in Africa. To date, Reliance Health has raised $48M in total funding, including a $6M Series A funding round in January 2020 led by Partech, with participation from Y Combinator, LoftyInc Capital, Golden Palm Investments, Ventures Platform, and Picus Capital.

Reliance Health uses technology to bring more affordable and accessible healthcare to leading companies in emerging markets including Biersdorf Nivea, Jumia, PWC, Merrybet, Regus, and others. Reliance has averaged 3.5x YOY revenue growth and offers an integrated approach that includes flat fee healthcare plans, telemedicine, prescription delivery, and a combination of partner and proprietary healthcare facilities in one single platform with one single fee. Headquartered in Lagos, Nigeria and Austin, Texas, Reliance Health began operations in Nigeria in 2015 as a telemedicine-focused startup, Kangpe, founded by Femi Kuti, Opeyemi Olumekun, and Matthew Mayaki, and later expanded into a single-fee healthcare provider to better address the complex, evolving needs of patients.

This new Series B investment will accelerate Reliance Health’s efforts in expanding the platform in emerging markets around the world while adding new products that complement existing proprietary technology, facilities, and partnerships. Reliance will also leverage the funds to hire additional top talent.

“Healthcare in emerging markets is often overlooked by private initiatives because it’s an extremely complex challenge to solve. At Reliance Health, by leveraging new innovations to break the constraints of legacy solutions, we believe there is an opportunity to solve some of these tough problems and even for aspects of healthcare in emerging markets to leapfrog to other parts of the world. We are excited to work with our investors towards bringing affordability and accessibility in healthcare to underserved markets, ultimately saving lives around the world,” said Femi Kuti, Reliance Health CEO and Co-Founder.

“General Atlantic is thrilled to announce our first technology investment in Africa in Reliance Health, backing a team focused on improving healthcare quality for millions of patients in Nigeria and abroad,” said Chris Caulkin, Head of EMEA Technology and Managing Director at General Atlantic. “We have been consistently impressed by Femi and Ope, who exemplify the entrepreneurialism and innovation we see across the African continent. We look forward to sharing our experience as a leading global growth equity investor in support of Reliance Health’s exciting and important mission.”

“We led Reliance Health’s Series A because we saw a team that combines great vision with superb execution. They have proven this by delivering a product that is successful with large corporate as well as micro-businesses, opening up access to healthcare for underserved segments of the population. All of the Partech team feels proud and excited to see top global investors join the company as it scales in Nigeria as well as new markets,” said Tidjane Dème, General Partner at Partech.

“Financial barriers prevent millions of people from receiving the life-saving and life-improving care that they need in low- and middle-income countries. Ensuring equitable access to healthcare coverage is something we care deeply about as mission-driven healthcare investors, and we’re honored to partner with Femi Kuti and the entire Reliance Health team to help scale their offering to achieve the largest potential impact,” said Jeff Trost, Managing Partner at Laerdal Million Lives Fund.

About Reliance Health

Reliance Health is a healthcare company using technology to make healthcare more affordable and accessible. Using an integrated approach that includes affordable health insurance, telemedicine, and a combination of partner and proprietary healthcare facilities. In its five years, Reliance has impacted over 200,000 lives, 600 companies, and has risen to become one of the leading digital health providers in emerging markets. The company employs over 230 “Rhomans”, has been recognized on “Jobberman’s 2019 Top 100 Companies in Nigeria” list, and was shortlisted on Techpoint Africa’s “Most Outstanding HealthTech Startup 2021” list.

For more information, please visit www.getreliancehealth.com

Follow us on LinkedIn

About General Atlantic

General Atlantic is a leading global growth equity firm with more than four decades of experience providing capital and strategic support for over 445 growth companies throughout its history. Established in 1980 to partner with visionary entrepreneurs and deliver lasting impact, the firm combines a collaborative global approach, sector-specific expertise, a long-term investment horizon, and a deep understanding of growth drivers to partner with great entrepreneurs and management teams to scale innovative businesses around the world. General Atlantic currently has over $86 billion in assets under management inclusive of all products as of September 30, 2021, and more than 215 investment professionals based in New York, Amsterdam, Beijing, Hong Kong, Jakarta, London, Mexico City, Mumbai, Munich, Palo Alto, São Paulo, Shanghai, Singapore, and Stamford. For more information on General Atlantic, please visit the website: www.generalatlantic.com.

About Partech

Born in San Francisco and Paris, Partech is one of the most active tech investors in the world, bringing together capital, operational experience, and strategic support for entrepreneurs at seed, venture and growth stages. The current portfolio includes 200+ companies in more than 30 countries, of which 14 are valued at more than $1B.

Media Contacts

Mary Armstrong & Emily Japlon
General Atlanticmedia@generalatlantic.com

Categories: News

Tags:

Nordic Capital invests in CARE Fertility in partnership with management to support CARE’s entry into new international markets

Nordic Capital
January 31 2022
Nordic Capital invests in CARE Fertility in partnership with management to support CARE’s entry into new international markets Image

 

Nordic Capital today announced the agreement to buy CARE Fertility (“CARE”), a leading fertility clinic group in the UK. The investment is made in partnership with CARE’s management team and will support the company’s next phase and international growth ambitions. Together with management, Nordic Capital will continue to drive improvements in clinical outcomes by investing in research to develop new techniques, strengthen the company’s highly successful integrated data driven operating model, focus on driving international expansion and investing in the company to benefit both employees and patients.

CARE has been at the forefront of IVF science and clinical technology for over 25 years. It operates 24 full-service and satellite fertility clinics across the UK and Ireland, offering highly advanced and effective procedures to support patients on their journey to parenthood. CARE has helped in the delivery of over 51,000 babies since it was founded in 1997. The company has an outstanding reputation based on its excellent success rates, high medical standards and clinical leadership.

Nordic Capital is one of the most experienced healthcare investors with 33 investments across Europe and North America and over EUR 8.6 bn invested in the sector since its inception in 1989. The investment in CARE lies at the heart of Nordic Capital’s healthcare investment strategy and focus on responsible investments and will be made as part of its mid-market strategy.

“We strongly believe that Nordic Capital is the best partner for CARE on the next step of our journey to helping even more patients. Nordic Capital has an extensive history of successful growth acceleration in leading healthcare services providers and will help us drive the growth of clinics and operations and further enhance our clinical excellence to be able to help more patients,” says David Burford, CEO, CARE.

“CARE is a leader in the fertility services area in the UK with its clinical excellence and persistent focus on continuously improving success rates for the benefit of its patients. We have been particularly impressed by the company’s management team, high medical standards and successful operating model,” said Alfa Chan, Partner, Nordic Capital Advisors, focusing on mid-market healthcare investment opportunities.

“Nordic Capital shares CARE’s vision and growth ambitions to become a truly international fertility services platform and looks forward to supporting its organic and inorganic growth with experience, expertise and financial strength,” said Joakim Lundvall, Partner, who leads Nordic Capital Advisors’ mid-market team.

“The IVF market is growing strongly due to an increase in infertility impacted by many different factors, contributing to an increased demand from patients for fertility treatments. In addition, there continues to be a growing awareness and acceptance of IVF treatments,” says Raj Shah, Partner and Head of Healthcare, Nordic Capital Advisors.

The acquisition of CARE was made from Silverfleet Capital.

Completion of the transaction is expected to occur at the end of February 2022 and is not subject to further closing conditions. The financial terms of the transaction were not disclosed.

 

Press contacts:

Nordic Capital
Katarina Janerud, Communications Manager
Nordic Capital Advisors
Tel: +46 8 440 50 50
e-mail: katarina.janerud@nordiccapital.com

CARE Fertility
David Burford, CEO
Tel: +44 (0) 115 852 8100
e-mail: david.burford@carefertility.com

 

About CARE Fertility

CARE Fertility is one of the largest independent providers of fertility treatment in the UK, performing more IVF cycles per year than any of its competitors. Founded in 1997 and based in Nottingham, England, CARE operates 15 full-service clinics and 9 satellite facilities providing extensive coverage across the UK and the Republic of Ireland. Since inception, CARE has been supported by a strong scientific and clinical backbone with the founder, Simon Fishel, being part of the team involved in the birth of the world’s first IVF baby in 1978. In the decades since, CARE has pioneered more effective fertility treatments through its extensive research and development operations, using data analytics and clinical expertise to introduce new treatments such as CAREmaps and chromosome screening, which improve the patients’ chance of success. Today, CARE has success rates which rank among the highest in the UK with its 560 employees including over 160 embryologists and doctors having aided in the conception of over 51,000 babies since inception.

 

About Nordic Capital

Nordic Capital is a leading private equity investor with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. Nordic Capital focuses on selected regions and sectors where it has deep experience and a long history. Focus sectors are Healthcare, Technology & Payments, Financial Services, and selectively, Industrial & Business Services. Key regions are Europe and globally for Healthcare and Technology & Payments investments. Since inception in 1989, Nordic Capital has invested more than EUR 19 billion in over 120 investments. The most recent entities are Nordic Capital X with EUR 6.1 billion in committed capital and Nordic Capital Evolution with EUR 1.2 billion in committed capital, principally provided by international institutional investors such as pension funds. Nordic Capital Advisors have local offices in Sweden, the UK, the US, Germany, Denmark, Finland, Norway and South Korea. For further information about Nordic Capital, please visit www.nordiccapital.com.

“Nordic Capital” refers to, depending on the context, any, or all, Nordic Capital branded entities, vehicles, structures and associated entities. The general partners and/or delegated portfolio managers of Nordic Capital’s entities and vehicles are advised by several non-discretionary sub-advisory entities, any or all of which are referred to as “Nordic Capital Advisors”

Categories: News

Tags:

Eurazeo invests in Cranial Technologies, the market leader in treating Infant Plagiocephaly

No Comments
Eurazeo

New York, 26 January 2022
Eurazeo, through its Mid-Large Buyout strategy, today announced it has acquired a majority stake
in Cranial Technologies, the market leader in treating infant plagiocephaly (commonly known as
“Flat Head Syndrome”). Eurazeo is investing over $200 million alongside an equity rollover from
the existing management team.

Founded in 1986, Cranial Technologies is the leading treatment provider and manufacturer of
helmets used for treating infants with various forms of plagiocephaly, brachycephaly and
scaphocephaly. Plagiocephaly is a common condition that affects nearly half of all babies born
each year. To date, Cranial Technologies has cared for over 300,000 babies using its FDA-approved
DOC Band® cranial orthotic. The Company delivers its helmets through 80 locations based in the
US, which it operates to treat patients directly, in addition to six licensed clinics internationally.
Eurazeo’s investment will support Cranial Technologies’ expansion across the US and other key
international markets by increasing awareness and expanding its clinical locations, in addition to
extending its product offerings into complementary business lines. Its strong pediatrician referral
network and custom manufacturing capabilities are solid strategic assets for Cranial Technologies’
development.

Marc Frappier, Member of the Executive Board, Managing Partner of Mid-Large Buyout, commented:
“We are delighted to announce the acquisition of Cranial Technologies, the fifth investment
for Eurazeo’s Mid-Large buyout strategy in the US. We are proud to be the partner of choice
for mid-sized companies with strong development ambitions. With Eurazeo, Cranial
Technologies will benefit from a deep healthcare expertise, a team of committed experts,
a global network and financial resources.”

Eric Sondag, Managing Director, Eurazeo, Mid-Large Buyout stated:
“Cranial Technologies is an industry leader that has pioneered a solution for a common
condition for infants, ensuring they reach their early development milestones
successfully. Debbie and her team have built a business centered on delivering superior
outcomes for patients and their families, which is evident in their customer satisfaction
metrics and loyalty with prescribing physicians. We’re pleased to partner with Debbie and
the rest of the management team to raise awareness of plagiocephaly and bring Cranial
Technologies’ outstanding products and top-rated care to growing families.”

Debbie James, CEO of Cranial Technologies, said:
“Since Cranial Technologies was founded over 30 years ago, our mission has been to
provide the best possible treatment, experience and outcome for every family who seeks
our care. We are excited to work with Eurazeo, a partner not only with an impressive track
record in scaling companies, but one who believes in our mission alongside our team.
Together, we look forward to welcoming new families around the world to our clinics. “

EURAZEO’S DEEP HEALTHCARE EXPERTISE PROVIDES LAUNCHPAD FOR INTERNATIONAL
GROWTH
With over 12% of private equity assets under management invested in the Healthcare sector,
Eurazeo provides deep industry expertise alongside financial and human capital to help mediumsized
Healthcare companies realize their growth potential.
Eurazeo’s Healthcare portfolio includes, in particular, DORC, a leading producer of opthalmic
surgery instruments and equipment, and Peters Surgical, manufacturer of single-use sterilized
surgical devices, in addition to multiple Digital Health and Biotech companies, all pursuing
increased digitization and global expansion in partnership with Eurazeo.
In addition, Eurazeo holds a majority stake in Kurma Partners, a French venture capital firm
specializing in biotechnology and medical innovation, and manages the Nov Santé fund on behalf
of the French Insurance Federation (FFA) and Caisse des Dépôts, created to accelerate the
digitization of the French healthcare industry.

ABOUT EURAZEO
 Eurazeo is a leading global investment company, with a diversified portfolio of €27 billion in
assets under management, including nearly €19.2 billion from third parties, invested in
450 companies. With its considerable private equity, venture capital, private debt as well as
real estate and infrastructure asset expertise, Eurazeo accompanies companies of all sizes,
supporting their development through the commitment of its nearly 300 professionals and
by offering deep sector expertise, a gateway to global markets, and a responsible and stable
foothold for transformational growth. Its solid institutional and family shareholder base,
robust financial structure free of structural debt, and flexible investment horizon enable
Eurazeo to support its companies over the long term.
 Eurazeo has offices in Paris, New York, Sao Paulo, Seoul, Shanghai, Singapore, London,
Luxembourg, Frankfurt, Berlin, Milan and Madrid.
 Eurazeo is listed on Euronext Paris.
 ISIN: FR0000121121 – Bloomberg: RF FP – Reuters: EURA.PA

ABOUT CRANIAL TECHNOLOGIES
 Founded in 1986, Cranial Technologies has provided plagiocephaly treatment to over 300,000
babies in 80 U.S. treatment centers. Our mission is to provide the best possible treatment,
experience and outcome for every family who seeks our care. Cranial Technologies invented
the DOC Band®, the first FDA-cleared cranial orthotic, and the DSi® (Digital Surface Imaging)
system. For more information, visit : www.cranialtech.com.

EURAZEO CONTACT
Virginie Christnacht
HEAD OF COMMUNICATIONS
vchristnacht@eurazeo.com
+33 (0)1 44 15 76 44
Pierre Bernardin
HEAD OF INVESTOR RELATIONS
pbernardin@eurazeo.com
+33 (0)1 44 15 16 76
PRESS CONTACT
Julia Fisher
EDELMAN
Julia.Fisher@edelman.com
+1 646 301 2968

Categories: News

Tags: